Guest Commentary in Drug Discovery World (DDW) by Aris Persidis, Biovista’s President Spring 2011 Drugs in development, on the market, or those that are shelved because of lack of efficacy, are excellent starting points for further development. Finding new indications for such drugs will benefit patients who will see a potential new therapy sooner, will … Read More
Year: 2011
BioWorld: Repurposing: Achilles Heel or Extra Leg to Stand On?
By Anette Breind, BioWorld Insight For Academia or Industry In the private space, Charlottesville, Va.-based Biovista Inc…Biovista has a positioning program that uses a bioinformatics approach to “develop all reasonable opportunities” for a drug, Persidis said, by tracking “without bias,” all biological effects of a compound…But Biovista is also developing its own in-house pipeline of existing … Read More
FirstWord: Drug Combinations: New Rules, New Opportunities
Biovista featured in FirstWorld’s latest report, “Drug Combinations: New Rules, New Opportunities” For years, drug therapy has been built on that basic equation. Yet as genomic biology sheds light on the astonishing intricacy of disease pathology, it is clear that drugs that combine several compounds must be developed in response. According to Biovista president … Read More
Biovista Awarded $0.5M to Participate in EC’s Personalized Medicine Initiative
Article in GEN on Biovista’s participation in the Eurpean “p-medicine” project. Drug repositioning specialist Biovista’s European affiliate has been awarded a $0.5 million grant to fund its participation in the European Commission’s €13.3 million (roughly $19.7 million), four-year p-medicine project focused on developing new tools and virtual physiological human (VPH) models to speed the development … Read More
Biovista Inc. Receives Prestigious EU Grant to use its Drug Repositioning Platform for Personalized Medicine
CHARLOTTESVILLE, Virginia and ATHENS, Greece, May 5, 2011 /PRNewswire/ — Biovista Inc. announced today that it’s EU affiliate has been awarded a prestigious grant worth $0.5 million, for research and development in the area of personalized medicine. The “p-medicine” project is a four-year, 13.3 million Euro co-funded effort under the European Community’s 7th Framework Programme … Read More